<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01705639</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-2011-005360-22</org_study_id>
    <nct_id>NCT01705639</nct_id>
  </id_info>
  <brief_title>Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene</brief_title>
  <acronym>MELAG</acronym>
  <official_title>Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Folkhalsan Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effect of 3 months of melatonin 4mg treatment on glucose tolerance in different variants
      of the melatonin receptor 1B gene will be evaluated. The following will be done at 0 and 3
      months:

        -  OGTT

        -  questionnaires about sleep and activity

        -  Actigraph

        -  Anthropometry

        -  Blood pressure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      http://www.sciencedirect.com/science/article/pii/S1550413116301607
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>3 months</time_frame>
    <description>Glucose tolerance is measured in OGTT: 0,30,60,90 and 120 minute values of glucose and insulin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sleep</measure>
    <time_frame>3 months</time_frame>
    <description>monitoring of sleep with questionnaires and activity monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activity</measure>
    <time_frame>3 months</time_frame>
    <description>Activity and sleep of the subjects is recorded with Actigraph at 0 and 3 months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Diabetes</condition>
  <condition>Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>melatonin 4mg od for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>All subjects receive the same dose of melatonin</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>Circadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  signed informed concent

          -  Known genotype for MTNR1B from the Botnia-ppp study

          -  Age 18-75 years

        Exclusion Criteria:

          -  Diabetes

          -  Positive GAD-ab

          -  Sever dysregulated hypertension

          -  glaucoma

          -  severe coronary heart disease or arrythmias

          -  previous or ongoing severe ventricle or duodenal ulcer

          -  psychosis or anxiety disorder

          -  regular use of sleep pills, antidepressants or neuroleptics

          -  creatinine &gt; 130 µmol/L

          -  elevated liver enzymes (ASAT, ALAT, ALP, GT, bilirubin) &gt; 3 times reference value

          -  inability to sign informed concent

          -  other factor with according to the physician may affect treatment or results.

          -  participation in other clinical study

          -  allergy to melatonin or other substance in the capsule

          -  hereditary galactose intolerance or glucose/galactose malabsorption

          -  intention to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leif Groop, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Lund, University of Helsinki</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tiinamaija Tuomi, Docent</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bo Isomaa, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Folkhalsan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Botniacentret Jakobstad</name>
      <address>
        <city>Jakobstad</city>
        <zip>68660</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vasa health care centre</name>
      <address>
        <city>Vasa</city>
        <zip>65200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1550413116301607</url>
    <description>Publication</description>
  </link>
  <results_reference>
    <citation>Tuomi T, Nagorny CLF, Singh P, Bennet H, Yu Q, Alenkvist I, Isomaa B, Östman B, Söderström J, Pesonen AK, Martikainen S, Räikkönen K, Forsén T, Hakaste L, Almgren P, Storm P, Asplund O, Shcherbina L, Fex M, Fadista J, Tengholm A, Wierup N, Groop L, Mulder H. Increased Melatonin Signaling Is a Risk Factor for Type 2 Diabetes. Cell Metab. 2016 Jun 14;23(6):1067-1077. doi: 10.1016/j.cmet.2016.04.009. Epub 2016 May 12.</citation>
    <PMID>27185156</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2012</study_first_submitted>
  <study_first_submitted_qc>October 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2012</study_first_posted>
  <last_update_submitted>January 3, 2017</last_update_submitted>
  <last_update_submitted_qc>January 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University</investigator_affiliation>
    <investigator_full_name>Tom Forsén</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>melatonin</keyword>
  <keyword>glucose tolerance</keyword>
  <keyword>sleep</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

